Compare Rocket Lab USA Inc (RKLB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rocket Lab USA Inc vs Zimmer Biomet Holdings Inc — how do they compare? Rocket Lab USA Inc trades at $68.21 (market cap $43.74B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Rocket Lab USA Inc is far larger — about 2.6× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rocket Lab USA Inc for 29 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| RKLB | ZBH | |
|---|---|---|
Market Cap | $43.74B | $16.95B |
Volume | 22,892,581 | 2,505,240 |
Sector | Industrials | Health |
52-Week High | $150.23 | $103.98 |
52-Week Low | $39.48 | $79.58 |
Typical Hold Time | 29 Days | 89 Days |
Enterprise Value | $41.57B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rocket Lab (RKLB) trades at $68.21, down 5.16% today, amid a bearish technical signal despite recent positive business developments. The company secured its largest-ever commercial Electron deal with Synspective for 20 launches, boosting its backlog past 100 missions. However, financials show negative profitability with a net income margin of -21.51% and elevated valuation ratios including P/S of 51.96. Technical indicators show bearish momentum with key support at $64.
The outlook remains mixed with strong analyst bullishness (76% buy ratings, $107 consensus target) contrasting with fundamental challenges. Investment opportunity lies in execution of the growing launch backlog and Neutron rocket development, while risks include sustained losses, SpaceX competition, and high valuation multiples requiring significant future growth to justify.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
